Intensity Therapeutics Inc. (INTS)
NASDAQ: INTSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
INTS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.01M
- EPS (TTM)
- -$3.89
- Dividend yield
- None
- 52-week range
- 3.21 – 43.50
- Day range
- 3.58 – 3.80
- Volume / Avg
- 19.04K / 25.89K
- Beta
- —
- Shares outstanding
- 3.26M
- Next earnings
- Nov 5, 2026
52-week range
INTS stock today
Shares of Intensity Therapeutics (INTS) finished lower on Oct 8 at $3.68, a drop of 3.16% or $0.12 per share, versus the S&P 500's 0.47% decline. At this level, INTS sits near the bottom of its 52-week range of $3.21 to $43.50: 91.5% below the high, set on Oct 30, 2025 and 14.6% above the low. INTS is down 64.1% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 48.4%.
Intensity Therapeutics has posted a net loss over the last twelve months (EPS of -$3.89), so its P/E ratio is not meaningful. Intensity Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Intensity Therapeutics
Company profileIntensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Lewis H. Bender M.A., M.B.A., M.S.
- Headquarters
- Shelton, CT
- Employees
- 5
- IPO year
- 2023
- Website
- intensitytherapeutics.com
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$19.33+425.27%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.94
Intensity Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PASGPassage Bio Inc. | 3.78 | -1.95% | $12.16M | vs INTS |
| LTRNLantern Pharma Inc. | 0.83 | -8.79% | $12.40M | vs INTS |
| PLURPluri Inc. | 1.00 | -3.85% | $12.61M | vs INTS |
| PHIOPhio Pharmaceuticals Corp. | 0.9731 | -2.69% | $11.30M | vs INTS |
| GDTCCytoMed Therapeutics Limited | 0.9449 | -3.56% | $11.28M | vs INTS |
| KPRXKiora Pharmaceuticals Inc. | 2.53 | 0.00% | $11.19M | vs INTS |
| BIVIBioVie Inc. Class A | 1.28 | -8.57% | $11.11M | vs INTS |
| LSTALisata Therapeutics Inc. | 1.20 | +2.56% | $12.96M | vs INTS |
Indexes, lists and sector
Appears in lists
Intensity Therapeutics stock FAQ
What is Intensity Therapeutics's stock price today?
INTS last traded at $3.68 as of Oct 8, 4:00 PM EDT, down 3.16% on the day. Prices are delayed at least 15 minutes.
Does Intensity Therapeutics pay a dividend?
No. Intensity Therapeutics does not currently pay a regular cash dividend.
When is Intensity Therapeutics's next earnings date?
Intensity Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.94.
Who is Intensity Therapeutics's CEO?
Mr. Lewis H. Bender M.A., M.B.A., M.S. is the chief executive officer of Intensity Therapeutics Inc., which has about 5 employees.
Has INTS ever split its stock?
Yes. The most recent INTS stock split was a 1-for-25 split on Feb 19, 2026.
What is the INTS 52-week high?
The 52-week high for INTS is $43.50 and the 52-week low is $3.21. The stock is currently 91.5% below its high.